KAT Innovation has demonstrated outstanding early-stage traction through global recognition, successful funding, and clinical progress. Since inception, we've raised over CAD $1 million in non-dilutive grants for R&D, prototyping, and clinical validation. In 2024, we were chosen as one of only 8 startups (from 250) for the prestigious mHUB MedTech Accelerator in Chicago, gaining USD $250,000 equity funding and mentorship. We also secured a spot in the MassChallenge U.S. Early Stage Cohort, selected as 128 from 1,300+ applicants.
Since 2020, KAT Innovation has earned 18 international awards and distinctions, including:
Centech Montréal cohort
Fall 2020
CreaVienne, France
March 2021
Recognition by BestStartup.ca
May 2021
Startup of the Year, Montreal NewTech Gala
December 2021
Grande Messe de Startup Montréal, MTL Connecte
May 2022
C2 Montréal Emerging Entrepreneurs
June 2022
Taiwan Mobileheroes Connectivity Innovation Challenge
November 2022
ADRIQ Innovation Awards Gala
November 2022
Boston IMPACT M2D2 Accelerator (only Canadian company)
February 2023
Startup Canada
April 2023
FemTech Paris Accelerator Program
September 2023 – March 2024
Via FemTech Lab London
Q1 2024
FemTech Lab, London
February 2024
AcexHealth Accelerator, Spain
March 2024
Health Orbit Call by the Canadian Space Agency & Medteq+
March 2024
"Win the Future" Global Entrepreneur Competition, Suzhou, China
May 2024
MassChallenge U.S. Early-Stage Cohort
May 2024
mHUB Chicago MedTech Program
November 2024 – May 2025
These achievements demonstrate our consistent global traction, innovation leadership, and growing confidence from evaluators, investors, and strategic partners across North America, Europe, and Asia.